Evidence map›Paper›PMID 35664313›Full record

ArticleFrontiers in genetics2022

Omeprazole Treatment Failure in Gastroesophageal Reflux Disease and Genetic Variation at the

Ping Siu Kee, Simran D S Maggo, Martin A Kennedy, Murray L Barclay, Allison L Miller, Klaus Lehnert, Maurice A Curtis, Richard L M Faull, Remai Parker, Paul K L Chin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Genetic variants ofJournal of Taibah University Medical Sciences · 2026
    Article
  2. Review
  3. Review
  4. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  5. Review
  6. IsGenes · 2024
    Article
  7. Review
  8. Article
  9. Article
  10. The pharmacogenetics ofFrontiers in pharmacology · 2023
    Article
  11. Review
  12. Distribution of a novelFrontiers in genetics · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ping Siu KeeDepartment of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.
Simran D S MaggoDepartment of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.
Martin A KennedyDepartment of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.
Murray L BarclayDepartment of Medicine, University of Otago, Christchurch, New Zealand.
Allison L MillerDepartment of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.
Klaus LehnertFaculty of Science, University of Auckland, Auckland, New Zealand.
Maurice A CurtisFaculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Richard L M FaullFaculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Remai ParkerFaculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Paul K L ChinDepartment of Medicine, University of Otago, Christchurch, New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Omeprazole is extensively used to manage gastroesophageal reflux disease (GERD). It is primarily metabolized by CYP2C19. The

Indexed as

CYP2C19CYP2C:TGGERDomeprazolepharmacogeneticsrefluxrefractoryultrarapid metabolizer

Identifiers

PMID35664313
PMCPMC9160307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.